Characterization of Pseudomonas aeruginosa in the Angiology Department
Keywords:
Pseudomonas aeruginosa, antimicrobial resistance, multi-resistance, resistance phenotypesAbstract
Introduction: it has been observed the emergence of multidrug-resistant strains of Pseudomonas aeruginosa on a global scale during the last decades. This opportunistic pathogen, widely associated with healthcare-associated infections, produces mechanisms of resistance to various antibiotics.Objective: to enumerate known risk factors of patients and describe the resistance pattern of Pseudomonas aeruginosa to antimicrobials.
Methods: a descriptive, cross-sectional study was carried out in the Angiology Service of the “Camilo Cienfuegos” Hospital from Sancti Spíritus between July 1st and December 31st, 2017 about Pseudomonas aeruginosa isolates in purulent samples from patients with healthcare-associated infections. The population was 47 samples. The automated Vitek® 2 Compact system was used to confirm the diagnosis and determine antimicrobial susceptibility to 13 antibiotics tested.
Results: the main known risk factors found in the patients were type 2 diabetes mellitus and chronic arterial insufficiency. Resistance was maintained to B-lactam antibiotics, including carbapenemics in more than 50%; however, low levels of resistance to aminoglycosides, fluoroquinolones, tigecycline and colistin were maintained.
Conclusions: type 2 diabetes mellitus was the main risk factor in patients admitted to the Angiology Department for contracting a healthcare-associated infection due to Pseudomonas aeruginosa, B-lactams were highly resistant and colistin may be a possible treatment option.
Downloads
References
1.Arias Flores CR, Rosado Quiab U, Vargas Valerio A, Grajales Muñiz. Los microorganismos causantes de infecciones nosocomiales en el Instituto Mexicano del Seguro Social. Rev Med Inst Mex Seguro Soc [Internet]. 2016 [citado 03/02/2019];54(1):20-4. Disponible en: http://www.medigraphic.com/pdfs/imss/im-2016/im161d.pdf
2.Pseudomonas, Acinetobacter y bacterias gramnegativas infrecuentes. En: Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA. Jawetz, Melnick y Adelberg: microbiología médica [Internet]. 25a ed. México: McGraw-Hill; 2011 [citado 03/02/2019]. p. 227-230. Disponible en: https://cmapspublic3.ihmc.us/rid=1RP7PC45V-WZK14Y-1H7Z/Microbiologia_medica_Jawetz.pdf
3.Hernández A, Yagüe G, García Vázquez E, Simón M, Moreno Parrado L, Canteras M, et al. Infecciones nosocomiales por Pseudomonas aeruginosa multiresistente incluido carbapenémicos: factores predictivos y pronósticos. Estudio prospectivo 2016-2017. Rev Esp Quimioter [Internet]. 2018 [citado 03/02/2019];31(2):123-130. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159385/
4.Álvarez Otero J, Lamas Ferreiro JL, González González L, Rodríguez Conde I, Fernández Soneira MJ, Arca Blanco A, et al. Resistencia a carbapenemas en Pseudomonasa eruginosa aisladas en urocultivos. Rev Esp Quimioter [Internet]. 2017 [citado 03/02/2019];30(3):183-194. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=6317082
5.Olaechea PM, Insausti J, Blanco A, Luque P. Epidemiología e impacto de las infecciones nosocomiales. Med Intensiva [Internet]. 2010 [citado 03/02/2019];34(4):256-267. Disponible en: https://www.medintensiva.org/es-epidemiologia-e-impacto-infecciones-nosocomiales-articulo-S0210569109001673. https://doi.org/10.1016/j.medin.2009.11.013
6.Molina J, Cordero E, Palomino J, Pachón J. Aminoglucósidos y polimixinas. Enferm Infecc Microbiol Clin [Internet]. 2009 [citado 03/02/2019];27(3):178-88. Disponible en: https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-aminoglucosidos-polimixinas-S0213005X09000986. https://doi.org/10.1016/j.eimc.2009.02.001
7.Hospital Provincial General “Camilo Cienfuegos”. Informes anuales de Microbiología de aislamientos y resistencia antimicrobiana de bacilos no fermentadores, para Comité de Control de Infecciones Asociadas a la Asistencia Sanitaria del Hospital Provincial General “Camilo Cienfuegos”, 2013-2017. Sancti Spíritus: Hospital Provincial General “Camilo Cienfuegos”; 2017.
8.Clinical And Laboratory Standards Institute. CLSI M100-S26. Performance Standards for Antimicrobial Susceptibility Testing [Internet]. 26th ed. Wayne, PA: CLSI; 2016 [citado 03/02/2019]. Disponible en: https://webstore.ansi.org/standards/clsi/clsim100s26
9.Pseudomonas y bacterias relacionadas. En: Murray PR, Rosenthal KS, Pfaller MA. Microbiología Médica. 8va ed. España: Elsevier; 2017. p. 272-277.
10.Gorrín Alemán IC, Rodríguez Pérez R, Rodríguez Rodríguez JA. Aislamientos de Pseudomonas aeruginosa en secreciones de pacientes hospitalizados aisladas de enero del 2006 a diciembre del 2010 en el Hospital Provincial Universitario “Arnaldo Milián Castro”. Acta Méd Centro [Internet]. 2012 [citado 03/02/2019];6(3):9-16. Disponible en: http://www.revactamedicacentro.sld.cu/index.php/amc/article/view/738
11.Slekovec C, Robert J, Trystram D, Delarbre JM, Merens A, van der Mee-Marquet N, et al. Pseudomonas aeruginosa in French hospitals between 2001 and 2011: back to susceptibility. Eur J Clin Microbiol Infect Dis [Internet]. 2014 [citado 03/02/2019]; 33(10):1713-1717. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24800929/. https://doi.org/10.1007/s10096-014-2125-8
12.Cobo Martínez F, Bermúdez Ruiz P, Manchado Mañas P. Situación actual de la resistencia de Pseudomonas aeruginosa a los antimicrobianos. Rev Esp Quimioterap [Internet]. 2003 [citado 03/02/2019];16(4):450-452. Disponible en: http://www.seq.es/seq/0214-3429/16/4/450.pdf
13.Pereira Santos Gonçalves DC, Mori Lima AB, Netto de Oliveira Leão LS, Rodrigues do Carmo Filho J, Pimenta FC, Gonçalves Vieira JD. Detecção de metalo-beta-lactamase em Pseudomonas aeruginosa isoladas de pacientes hospitalizados em Goiânia, Estado de Goiás. Rev Soc Bras Med Trop [Internet]. 2013 [citado 03/02/2019];42(4):411-414. Disponible en: https://www.scielo.br/j/rsbmt/a/G9CN4hS9RTWw5ychjRpxQxx/abstract/?lang=en. https://doi.org/10.1590/S0037-86822009000400010
14.Bou Arabelo G, Chaves Sánchez F, Oliver Palomo A, Oteo Iglesias J. Métodos microbiológicos para la vigilancia del estado de portador de bacterias multirresistentes. En: Cercenado Mansilla E, Cantón Moreno R, editores. Procedimientos en Microbiología Clínica [Internet]. Madrid: Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; 2015 [citado 03/02/2019]. Disponible en: https://www.seimc.org/contenidos/documentoscientificos/procedimientosmicrobiologia/seimc-procedimientomicrobiologia55.pdf
15.González Escalante E. Metalo-β-lactamasas: ¿el fin de los β-lactámicos? Rev Peru Epidemiol [Internet]. 2012 [citado 03/02/2019];16(3):1-8. Disponible en: https://www.redalyc.org/pdf/2031/203125431002.pdf
16.Zambrano A, Herrera N. Susceptibilidad antimicrobiana de cepas de Pseudomonas aeruginosa aisladas en el laboratorio del Hospital Regional Dr. Leonardo Guzmán de Antofagasta, Chile. Rev Chil Infectol [Internet]. 2004 [citado 03/02/2019];21(2):117-124. Disponible en: https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182004000200003. http://dx.doi.org/10.4067/S0716-10182004000200003
17.Medell Gago M, Hart Casares M, Mora Diaz I. Acinetobacter baumannii versus Pseudomonas aeruginosa. Comportamiento en pacientes críticos con ventilación mecánica. Rev Cubana Med [Internet]. 2012 [citado 03/02/2019];51(3):239-246. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232012000300005
18.Smith S, Ganiyu O, John R, Fowora M, Akinsinde K, Odeigah P. Antimicrobial resistance and molecular typing of pseudomonas aeruginosa isolated from surgical wounds in Lagos, Nigeria. Acta Med Iran [Internet]. 2012 [citado 03/02/2019];50(6):433-438. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22837123/
19.European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) [Internet]. Stockholm: ECDC; 2014 [citado 03/02/2019]. Disponible en: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/antimicrobial-resistance-europe-2014.pdf
20.Cobos-Trigueros N, Solé M, Castro P, Torres JL, Hernández C, Rinaudo M, et al. Acquisition of Pseudomonas aeruginosa and its resistance phenotypes in critically ill medical patients: role of colonization pressure and antibiotic exposure. Crit Care [Internet]. 2015 [citado 03/02/2019];19(1):218. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432505/. https://dx.doi.org/10.1186%2Fs13054-015-0916-7
21.Minchella A, Molinari L, Alonso S, Bouziges N, Sotto A, Lavigne JP. Évolution de la résistance aux antibiotiques de Pseudomonas aeruginosa dans un centre hospitalier universitaire entre 2002 et 2006. Pathol Biol (Paris) [Internet]. 2010 [citado 03/02/2019];58(1):1-6. Disponible en: https://www.em-consulte.com/article/243190/evolution-de-la-resistance-aux-antibiotiques-de-ps. https://dx.doi.org/10.1016/j.patbio.2009.08.002
22.Lambert PA. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J R Soc Med [Internet]. 2002 [citado 03/02/2019];95(Suppl 41):22-26. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1308633/
23.Nseir S, Grailles G, Soury-Lavergne A, Minacori F, Alves I, Durocher A. Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensive-care unit admission. Clin Microbiol Infect [Internet]. 2010 [citado 03/02/2019];16(7):902–908. Disponible en: https://pubmed.ncbi.nlm.nih.gov/19694760/. https://doi.org/10.1111/j.1469-0691.2009.03027.x
24.LLoria M. Manejo de las Infecciones por Organismos Multirresistentes. Infecciones por Pseudomonas aeruginosa. Sociedad Argentina de Terapia Intensiva [Internet]. Buenos Aires: Comité de Infectología Crítica; 2009 [citado 03/02/2019]. Disponible en: https://www.sati.org.ar/images/comites/infectologia/2009-Infecciones-por-P-aeruginosa-en-UTI-%20Revision.pdf
25.Zahedi Bialvaei A, Samadi Kafil H. Colistin, mechanisms and prevalence of resistance. Curr Med Res Opin [Internet]. 2015 [citado 03/02/2019];31(4):707-721. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25697677/. https://doi.org/10.1185/03007995.2015.1018989
26.Justo JA, Bosso JA. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy [Internet]. 2015 [citado 03/02/2019];35(1):28-33. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25266910/. https://doi.org/10.1002/phar.1493
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms:
- Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
- Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
- Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
15 junio 2025
